Skip to main content
. 2016 Jul 6;7(34):55128–55140. doi: 10.18632/oncotarget.10422

Figure 7. Vemurafenib treatment results in loss of MITF and gain of FOXD3 and ERBB3.

Figure 7

Representative western blots showing MITF loss and subsequent gain of ERBB3 and FOXD3 protein after 2 weeks of vemurafenib treatment (0.5μM) in the WM983B and SKMEL28 cell lines. Vemurafenib-cultured cells were performed in triplicate. Histone H3 was used as loading control.